GlassScriptPhysician profile
Konrad R Kijewski
NPI 1184767048
$5,716.00
in general payments reported to CMS, 2019-2025
33 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $752 · 2021: $2,037 · 2022: $369 · 2023: $346 · 2024: $597 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.74 |
| Education | $143.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,667.08 | 2019-2025 | Proclaim, Octrode, Penta |
| Amgen INC. | $538.47 | 2019-2024 | Prolia, Evenity |
| Si-Bone, INC. | $515.95 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $378.84 | 2021 | |
| Nevro Corp. | $307.32 | 2021-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.30 | 2019-2022 | |
| Boston Scientific Corporation | $256.39 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $230.44 | 2019-2021 | |
| Abbvie INC. | $140.48 | 2021-2022 | |
| Bioventus LLC | $136.05 | 2019 | |
| Lilly USA, LLC | $131.82 | 2019-2021 | |
| Treace Medical Concepts, INC. | $127.07 | 2024 | |
| Allergan, INC. | $124.72 | 2019-2021 | |
| Pfizer INC. | $115.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $102.89 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $84.26 | 2020-2023 | Onzetra Xsail, Contrave |
| Vertex Pharmaceuticals Incorporated | $72.38 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $64.40 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $59.19 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $49.18 | 2021 | |
| Scilex Pharmaceuticals INC. | $48.23 | 2019-2024 | |
| Redhill Biopharma INC. | $43.07 | 2020 | |
| Averitas Pharma INC. | $42.23 | 2023-2024 | Qutenza |
| Trevena, INC. | $29.06 | 2021 | |
| Baudax Bio INC. | $23.87 | 2021 | |
| Grt US Holding, INC. | $18.79 | 2020 | |
| Daiichi Sankyo INC. | $18.32 | 2019 | |
| Pacira Therapeutics, INC. | $17.63 | 2021 | |
| Ibsa Pharma INC. | $16.08 | 2020 | |
| Zyla Life Sciences, INC. | $15.23 | 2020 | |
| Biodelivery Sciences International, INC. | $14.45 | 2020 | |
| Depuy Synthes Sales INC. | $12.80 | 2021 | |
| Kaleo, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Konrad Kijewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.